NovoArc GmbH is an Austrian biotechnology company founded in 2021 as a spin-off from TU Wien and headquartered in Vienna. It develops and produces specialized tetraether lipids derived from extremophilic archaea for use in pharmaceutical drug formulations and delivery systems. The company's lipid technologies are designed to provide enhanced stability across various conditions, supporting applications for small molecules, proteins, nucleic acids, and complex therapeutics such as mRNA-based treatments.
In June 2026, NovoArc entered a strategic collaboration with Avanti Polar Lipids, a wholly owned subsidiary of Croda International Plc, to expand availability of its lipids for global pharmaceutical research use, with potential future scaling toward clinical and commercial manufacturing.
Official website: novoarc.at
